ArticleNPJ Regenerative medicine2025
Label-free in-line characterization of immune cell culture using quantitative phase imaging.
Article in NPJ Regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Foundation model cascades enable zero-shot microscopy image analysis for cell therapy manufacturing.Cytotherapy · 2026Article
- Qualitative and quantitative assessment ofBiomedical optics express · 2026Article
- Article
- Nondestructive, High-Resolution T Cell Characterization and Subtyping via Deep-UV Microscopy.BME frontiers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Cell therapies, such as T cell immunotherapies, hold significant promise for treating complex diseases; however, their widespread adoption has been hindered by challenges related to monitoring cells during culture, which has affected their consistency, potency, and cost. Here, we present a compact, low-cost, label-free quantitative phase imaging (QPI) platform to enable continuous, non-destructive, in-line monitoring of T cell cultures within bioreactors. We further develop quantitative, image-based assays that accurately characterizes T cell culture viability and activation from over 50 independent donors-including therapeutically relevant CAR-T cells - while also preserving culture sterility and eliminating the need for disruptive sampling and endpoint assays. Our findings establish a QPI-pipeline for label-free, in-line cell monitoring and characterization which can significantly improve cell manufacturing processes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.